Back Pain Stem Cell Therapy Doctors Tampa
http://Trinity-Spine.com (727) 372-9922 Stem Cell Therapy Doctor Reviews Everyone was so nice and helpful. They calmed my nerves about having to get this done, and even had really late hours...
By: Anderson Flanders
Read the rest here:
Back Pain Stem Cell Therapy Doctors Tampa - Video
(MENAFN - ProactiveInvestors)
Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis.
The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015.
Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor.
The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said.
This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product.
One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue.
Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue.
Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types.
Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC).
Go here to see the original:
Regeneus hits key stem cell manufacturing milestone
Copy of 0dKXZsceBerY 1
Utah Stem Cells offers a variety of services using Stem Cells and Platelet Rich Plasma. Our Stem Cell Joint Regeneration has proven very effective to our patients, and it #39;s the best alternative...
By: Bill Cimikoski
Read the original:
Copy of 0dKXZsceBerY 1 - Video
PHILADELPHIA -- The American Association for Cancer Research (AACR) is honoring Owen N. Witte, MD, founding director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research and distinguished professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles, with the 55th annual AACR G.H.A. Clowes Memorial Award at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.
Witte, who is also a Howard Hughes Medical Institute investigator and an elected fellow of the AACR Academy, is being recognized for his many contributions to the understanding of human leukemias, immune disorders, and epithelial cancer stem cells. Witte's work, which contributed to the development of several approved targeted therapies, has transformed the lives of patients with Philadelphia chromosome-positive leukemias and B-cell malignancies. He will present his lecture, "Finding Therapeutic Targets for Aggressive Prostate Cancer," Monday, April 20, 5:30 p.m. ET, in the Grand Ballroom of the Pennsylvania Convention Center.
The AACR and Eli Lilly and Company established the G.H.A. Clowes Memorial Award in 1961 to honor Dr. G.H.A. Clowes, a founding member of the AACR and research director at Eli Lilly. This award recognizes an individual with outstanding recent accomplishments in basic cancer research.
Witte's innovative work helped revolutionize modern cancer treatment by defining tyrosine kinases as crucial drug targets in human disease. Most notably, he pinpointed the molecular consequences of the Philadelphia (Ph) chromosome abnormality present in chronic myelogenous leukemia (CML) and related types of leukemia and defined the tyrosine kinase activity of the ABL gene product. These findings played a crucial role in the subsequent development of ABL kinase-targeted therapies, including imatinib (Gleevec), which remains the front-line treatment for Ph-positive CML.
In addition to his research involving ABL, Witte also co-discovered Bruton agammaglobulinemia tyrosine kinase (BTK). This particular kinase is essential for B-cell maturation and when mutated, results in the onset of the immunodeficiency disease, X-linked agammagloblulinemia. Recent studies involving this protein have resulted in the U.S. Food and Drug Administration approval of ibrutinib (Imbruvica), a selective BTK inhibitor, for the treatment of chronic lymphocytic leukemia mantle cell lymphoma, and Waldenstrm macroglobulinemia.
More recently, Witte's work has focused on defining the epithelial stem cell populations that contribute to prostate cancer. He is currently using mass spectrometry approaches to identify kinases that could be potential therapeutic targets for human prostate cancer.
"Much progress has been made in the area of personalized cancer medicine due to the dedication of scientists and physicians around the world, many of whom I've had the pleasure of working with through the AACR's innovative initiatives," said Witte. "But much more work is needed as we seek to understand cancer, which is not a single disease but rather many diseases that develop differently. I thank the AACR for their leadership in this effort and am honored to receive the Clowes Memorial Award."
An active AACR member, Witte has served on the AACR board of directors and several grant review committees. He is a past recipient of the AACR-Richard and Hinda Rosenthal Award and a co-leader of the Stand Up to Cancer Dream Team: Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer. Additionally, he is also serving an appointed term on the President's Cancer Panel.
Witte has been recognized throughout his career with numerous honors. He has received the Nakahara Memorial Lecture Prize, the Cotlove Lectureship from the Academy of Clinical Laboratory Physicians and Scientists, the de Villiers International Achievement Award from the Leukemia and Lymphoma Society, the Warren Alpert Prize, and is elected member of the Institute of Medicine, National Academy of Sciences, and fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.
Witte received his medical degree from Stanford University School of Medicine in California, and was a postdoctoral fellow at the Center for Cancer Research at the Massachusetts Institute of Technology in Cambridge. He joined the UCLA faculty in 1980.
The rest is here:
Dr. Owen Witte recognized with AACR G.H.A. Clowes Memorial Award
Beverly Hills, California (PRWEB) April 07, 2015
Dr. Raj, the top Orthopedic Surgeon in Beverly Hills and Los Angeles, is now offering stem cell therapy to heal chronic tendonitis. The treatment works exceptionally well for those suffering from tendonitis of the rotator cuff, achilles, elbow and knee. For more information and scheduling, call (310) 247-0466.
As a pioneer in regenerative medicine, Dr. Raj has been helping patients with degenerative arthritis achieve relief and avoid joint replacements for years with stem cell procedures. By adding the procedures for tendonitis, Dr. Raj is now helping patients avoid potentially risky surgeries and get back to being more active for soft tissue related pain.
"Surgery for tendonitis is often not 100% successful for patients, and the rehabilitation period may take six months," states Dr. Raj. "With the stem cell therapy, pain relief is quick and athletes get back to sports faster!"
Regenerative medicine for tennis elbow has been shown in research studies to be effective at relief and helping avoid surgery. A 2013 study out of South Florida showed that 28 out of 30 patients with chronic tennis elbow avoided surgery and got back to being very active.
For several years in a row, Dr. Raj has been named the top orthopedic doctor in Los Angeles and Beverly Hills. He is an ABC News Medical Correspondent as well as a WebMD Medical Expert.
Hundreds of patients have benefited from stem cell procedures with Dr. Raj at Beverly Hills Orthopedic Institute. They come from all over Southern California, along with throughout the country. Call (310) 247-0466 for scheduling stem cell therapy with an orthopedic surgeon Beverly Hills trusts and respects.
Here is the original post:
Dr. Raj at Beverly Hills Orthopedic Institute Now Offering Stem Cell Therapy to Heal Chronic Tendonitis
Miami, FL (PRWEB) April 06, 2015
Regenestem Network, a subsidiary of the Global Stem Cells Group, has announced plans to attend the 23rd Annual World Congress on Anti-Aging Medicine (a4m) at the Diplomat Resort and Spa in Hollywood, Fla. Hosted by the American Academy of Anti-aging Medicine, the conference will be attended by physicians and medical practitioners from around the world.
Regenestem Network plans to showcase its upcoming stem cell training course, Adipose Derived and Bone Marrow Stem Cell course, with classes scheduled to be held May 9-10 and June 15-16, 2015 in Miami. The intensive, two-day course covers the latest technology and procedures in adipose and bone marrow stem cell therapies. Participants learn skills that can be used in their own practice and for career advancement.
A4m Conference Keynote speakers include Daniel G. Amen, MD, David Perlmutter, MD, FACN, ABIHM, and Gary Small, MD. All three will focus on disease prevention and optimized health through a proactive treatment approach. These world-renown speakers are scheduled to deliver insightful presentations, the latest research and breakthrough therapies in anti-aging medicine.
To learn more about the 23rd Annual World Congress on Anti-Aging Medicine, visit the a4m website. For more information on the Regenestem Network, visit the website at regenestemnetwork.com. For more information on the stem cell training classes, visit the http://www.stemcelltraining.net website, email bnovas(at)regenestem(dot)com, or call 849.943.2988.
About Regenestem Network:
Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.
Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
About the Global Stem Cell Group:
Read this article:
Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015
Autistic Minority International - CRPD side event - 2 April 2015
Side event on occasion of the UN #39;s World Autism Awareness Day 2015 "Medical Experimentation on Autistic Children: Fake Cures and Global Stem Cell Tourism", organized by Autistic Minority ...
By: Erich Kofmel
Read this article:
Autistic Minority International - CRPD side event - 2 April 2015 - Video
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D.
Bill describes his result one year after bone marrow stem cell therapy by Dr. Harry Adelson for low back pain caused by a degenerated and herniated lumbar disc.
By: Harry Adelson, N.D.
See the original post here:
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D. - Video
Life-changing results: Sandra Sharman is a private stem cell patient. Photo: Meredith O'Shea
Last week, Suzie Palmer, 44, travelled from her home in NSW to the Gold Coast for her second round of stem cell treatments for multiple sclerosis. OnTuesday morning,the wheelchair-bound poet underwent liposuction.
By 2.30pm, stem cells had been partially separated from her abdominal fat, suspended in plasma, and injected intravenously. Her doctor, Soraya Felix, is a cosmetic surgeon and molecular biologist with a sideline in regenerative medicine.
Palmer, a relentlessly upbeat and positive person, says the treatments have helped her cope better with heat, improved her mobility and flexibility and otherwise made her "feel like a normal human being". She has, she says, managed a few steps with a walker, still a long way from "running about, which is my dream".
Poster girl: Suzie Palmer is undergoing stem cell therapy for MS. Photo: Edwina Pickles
The rapidly growing stem cell industry is aglow with similarly positive testimonials, notably on behalf of practitioners who offer little documented scientific evidence of their success.
Advertisement
Suzie Palmer is literally the poster girl for stem cell tourism within Australia. You can find her smiling sweetly, along with Dr Felix, on the Facebook page of a group called the Adult Stem Cell Foundation. She is one of an unknown number of unwell Australians pinning their hopes on an unregulated industry that is now under review by the Therapeutic Goods Administration.
The TGA public consultation, which closed earlier this month, was prompted by long-standing concerns raised by Stem Cells Australia that a loophole in the regulations has allowed dozens of doctors across Australia to provide experimental treatments without the ethics committee oversight that registered clinical trials are subject to. These treatments invariably cost $10,000 and up. The loophole is this: while the use of donor stem cells in therapies is tightly regulated, the use of a patient's own stem cells is not.
Professor Martin Pera is the program leader of Stem Cells Australia, which is administered by the University of Melbourne and includes scientists from Monash University, the Walter and Eliza Hall Institute for Medical Research, the Florey Institute and the CSIRO, among others. They are engaged in a seven-year Australian Research Council project to answer the big questions about stem cells and the potential for reliable therapies.
See the original post:
Is a loophole in stem cell law helping new therapy to thrive, or allowing dubious science?
Stem cells help researchers peg rabies resistance
Researchers at Texas A M AgriLife Research have developed a new technology to determine sensitivity or resistance to rabies virus. We were able to create a novel platform such that we could...
By: AgriLife Today - Texas Agriculture News
More:
Stem cells help researchers peg rabies resistance - Video
How Nova Cells Institute uses stem cells in treatments, 562-916-3410
How Nova Cells Institute makes a difference using stem cells and Beacon Factor in treatments - learn more at http://www.novacellsinstitute.com.
By: NCIM
Read the rest here:
How Nova Cells Institute uses stem cells in treatments, 562-916-3410 - Video
Researchers map chromosomal changes that must take place before stem cells can be used to produce pancreatic and liver cells
IMAGE:These are pancreatic cells derived from embryonic stem cells. view more
Credit: UC San Diego School of Medicine
Stem cells hold great promise for treating a number of diseases, in part because they have the unique ability to differentiate, specializing into any one of the hundreds of cell types that comprise the human body. Harnessing this potential, though, is difficult. In some cases, it takes up to seven carefully orchestrated steps of adding certain growth factors at specific times to coax stem cells into the desired cell type. Even then, cells of the intestine, liver and pancreas are notoriously difficult to produce from stem cells. Writing in Cell Stem Cell April 2, researchers at University of California, San Diego School of Medicine have discovered why.
It turns out that the chromosomes in laboratory stem cells open slowly over time, in the same sequence that occurs during embryonic development. It isn't until certain chromosomal regions have acquired the "open" state that they are able to respond to added growth factors and become liver or pancreatic cells. This new understanding, say researchers, will help spur advancements in stem cell research and the development of new cell therapies for diseases of the liver and pancreas, such as type 1 diabetes.
"Our ability to generate liver and pancreatic cells from stem cells has fallen behind the advances we've made for other cell types," said Maike Sander, MD, professor of pediatrics and cellular and molecular medicine and director of the Pediatric Diabetes Research Center at UC San Diego. "So we haven't yet been able to do things like test new drugs on stem cell-derived liver and pancreatic cells. What we have learned is that if we want to make specific cells from stem cells, we need ways to predict how those cells and their chromosomes will respond to the growth factors."
Sander led the study, together with co-senior author Bing Ren, PhD, professor of cellular and molecular medicine at UC San Diego and Ludwig Cancer Research member.
Chromosomes are the structures formed by tightly wound and packed DNA. Humans have 46 chromosomes - 23 inherited from each parent. Sander, Ren and their teams first made maps of chromosomal modifications over time, as embryonic stem cells differentiated through several different developmental intermediates on their way to becoming pancreatic and liver cells. Then, in analyzing these maps, they discovered links between the accessibility (openness) of certain regions of the chromosome and what they call developmental competence - the ability of the cell to respond to triggers like added growth factors.
"We're also finding that these chromosomal regions that need to open before a stem cell can fully differentiate are linked to regions where there are variations in certain disease states," Sander says.
In other words, if a person were to inherit a genetic variation in one of these chromosomal regions and his or her chromosome didn't open up at exactly the right time, he or she could hypothetically be more susceptible to a disease affecting that cell type. Sander's team is now working to further investigate what role, if any, these chromosomal regions and their variations play in diabetes.
Read more from the original source:
'Open' stem cell chromosomes reveal new possibilities for diabetes
Orthopedic Stem Cell Therapy for Arthritic Joint Pain
Dr. Sergio Viroslav, board certified orthopedic surgeon and joint replacement specialist with The San Antonio Orthopaedic Group, appeared on Great Day SA on March 30th, 2015 to discuss the...
By: The San Antonio Orthopaedic Group
Original post:
Orthopedic Stem Cell Therapy for Arthritic Joint Pain - Video
Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center
How can PRP and stem cell therapy help you heal? Orlando Orthopaedic Center #39;s Dr. Matthew R. Willey explains. For more visit http://www.OrlandoOrtho.com.
By: OrlandoOrtho
More here:
Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video
DALLAS, April 2, 2015 /PRNewswire/ --
Lifescienceindustryresearch.com adds "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report" in its store. Recent months have seen the first iPSC clinical trial in humans, creation of the world's largest iPSC Biobank, major funding awards, a historic challenge to the "Yamanaka Patent", a Supreme Court ruling affecting industry patent rights, the announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond.
Is it worth it to get informed about rapidly-evolving market conditions and identify key industry trends that will give an advantage over the competition?
BrowsetheReportComplete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Reportathttp://www.lifescienceindustryresearch.com/complete-2013-14-induced-pl ....
Induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases. The cell type represents one of the most promising advances discovered within the field of stem cell research during the past decade, making this a valuable industry report for both companies and investors to claim in order to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends.
Report Applications
This global strategic report is produced for: Management of Stem Cell Product Companies, Management of Stem Cell Therapy Companies, Stem Cell Industry Investors
It is designed to increase your efficiency and effectiveness in:
Four Primary Areas of Commercialization
There are currently four major areas of commercialization for induced pluripotent stem cells, as described below:
See the original post here:
Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016
Antiaging Treatment by Fat Graft and Adipose-Derived Stem Cells Michael T. Longaker, MD, MBA
In this video, Michael T. Longaker, MD, MBA discusses the article Antiaging Treatment of the Facial Skin by Fat Graft and Adipose-Derived Stem Cells by Charles-de-S et al., appearing...
By: PRSJournal
More here:
Antiaging Treatment by Fat Graft and Adipose-Derived Stem Cells Michael T. Longaker, MD, MBA - Video
Stem Cell Connectivity {Duke University Research}
A Duke University team has discovered how stem cells build long, slender structures that may ferry signals from one place to another, connecting the stem cell to the critical information it...
By: Duke University
More:
Stem Cell Connectivity {Duke University Research} - Video
Testimonial John Edwards
John Edwards of Roatan provides a testimonial for his orthopedic stem cell treatments recently at GARM.
By: Global Alliance for Regenerative Medicine, Roatan, Honduras
Go here to read the rest:
Testimonial John Edwards - Video
When billions of dollars are at stake in scientific research, researchers quickly learn that optimism sells.
A new study published inScience Translational Medicineoffersa window into how hype arises in the interaction between the media and scientific researchers, and how resistant the hype machine is to hard, cold reality. The report'sfocus is on overly optimisticreporting on potentialstem cell therapies. Its findings are discouraging.
The study by Timothy Caulfield and Kalina Kamenova of the University of Alberta law school (Caulfieldis also on the faculty at the school of public health) found that stem cell researchers often ply journalists with "unrealistic timelines" for the development of stem cell therapies, and journalists oftenswallow these claims uncritically.
The authorsmostly blame the scientists, who need to be more aware of "the importance of conveying realistic ... timelines to the popular press." We wouldn't give journalists this much of a pass; writers on scientific topics should understand that the development of drugs and therapies can take years and involve myriad dry holes and dead ends. They should be vigilant againstgaudypromises.
That's especially true instem cell research, whichis slathered with so much money that immoderate predictions of success are common. The best illustration of that comes from California's stem cell program -- CIRM, or the California Institute for Regenerative Medicine -- a $6-billion public investment that was born in hype.
The promoters of Proposition 71, the 2004 ballot initiative that created CIRM, filled the airwaves with adsimplyingthat the only thing standing between Michael J. Fox being cured of Parkinson's or Christopher Reeve walking again was Prop. 71's money. Theycommissioned a studyassertingthat California might reap a windfall in taxes,royalties and healthcare savings up to seven times the size ofits $6-billion investment. One wouldn't build a storage shed on foundations this soft, much less a $6-billion mansion.
As we've observed before, "big science" programs create incentivesto exaggerateresults to meet the public's inflated expectations. The phenomenon was recognized as long ago as the 1960s, when the distinguished physicist Alvin Weinberg warnedthat big science "thrives on publicity," resulting in "the injection of a journalistic flavor into Big Science which is fundamentally in conflict with the scientific method.... The spectacular rather than the perceptive becomes the scientific standard."
Interestingly, the event used by the Alberta researchers as the fulcrum of their study has a strong connection to CIRM. It's the abrupt 2011 decision by Geron Corp.to terminate its pioneering stem cell development program. This was a big blow to the stem cell research community and to CIRM, which had endowed Geron with a $25-million loan for its stem cell-basedspinal cord therapy development. Then-CIRM Chairman Robert Klein II had called the loan a "landmark step."
There had been evidence, however, that CIRM, eager to show progress toward bringing stem cell therapies to market, had downplayed legitimate questions about the state of Geron's science and the design of the clinical trial. AndGeron had been criticized in the past for over-promising results.
In their study, Caulfield and Kamenova examined more than 300 articles appearing in 14 general-interest newspapers in the United States, Canada and Britain from 2010 to2013. They scrutinizedthe articles' reporting oftimelines for the "realization of the clinical promise of stem cell research" and their perspective on the future of the field generally. The U.S. newspapers were the New York Times, the Wall Street Journal, the Washington Post and USA Today.
Read the original post:
New study: Stem cell field is infected with hype
Cord Blood Banking with GeneCell
Learn the process of Cord Blood Banking with GeneCell and get the peace of mind you deserve. Cord blood contains stem cells that can be transfused to a patient to treat various diseases,...
By: genecellintl
Follow this link:
Cord Blood Banking with GeneCell - Video